Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.

摘要: Background/aims Sunitinib is a multi-targeted thyrosine kinase receptor inhibitor used in patients with advanced gastrointestinal stromal tumours (GISTs). We evaluated the efficacy and tolerability of sunitinib therapy Turkish GISTs. Methodology Between January 2001 April 2012, 57 who had progressive disease or experienced unacceptable toxicity during imatinib treatment from multiple centers were investigated retrospectively. Results Thirty-three male 24 female. The median age was 55 years (range; 16-84 years). Thirty-eight received for longer than 12 months, 13 6-12 6 less six months. clinical benefit 73.7%. Treatment-related adverse events reported 78% patients. Adverse generally mild to moderate intensity. progression free survival (PFS) overall (OS) that 10.8 months 23.9 respectively. time usage response independent prognostic factors PFS OS. Also, tumor size an factor PFS. Conclusions effective GISTs, 73.7% shows acceptable tolerability.